{"organizations": [], "uuid": "46ba893d254843522f3c00f913f806d82a1c1bc5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mithra-announces-last-subject-visi/brief-mithra-announces-last-subject-visit-in-estelle-phase-iii-study-in-eu-russia-idUSFWN1SA061", "country": "US", "domain_rank": 408, "title": "Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.389, "site_type": "news", "published": "2018-05-03T14:01:00.000+03:00", "replies_count": 0, "uuid": "46ba893d254843522f3c00f913f806d82a1c1bc5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mithra-announces-last-subject-visi/brief-mithra-announces-last-subject-visit-in-estelle-phase-iii-study-in-eu-russia-idUSFWN1SA061", "ord_in_thread": 0, "title": "Mithra Announces Last Subject Visit In Estelle Phase III Study In EU/Russia", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - Mithra Pharmaceuticals SA:\n* MITHRA ANNOUNCES LAST SUBJECT VISIT IN ESTELLE® PHASE III STUDY IN EU/RUSSIA AND COMPLETION OF ENDOMETRIAL SUBSTUDY\n* MITHRA ALSO ANNOUNCES THAT ENDOMETRIAL SAFETY SUBSTUDY HAS COMPLETED RECRUITMENT\n* ESTELLE PHASE III STUDIES REMAIN ON TRACK TO REPORT TOP-LINE RESULTS IN Q3 2018 FROM EUROPE/RUSSIA AND Q1 2019 FROM US/CANADA\n* IN US/CANADIAN STUDY LAST SUBJECT VISIT IS EXPECTED TO TAKE PLACE IN Q4 2018\n* PHASE III EUROPEAN/RUSSIAN STUDY OF ESTELLE® SEEN LOWER THAN EXPECTED DROP-OUT RATE WITH OVER 1,200 WOMEN COMPLETING MIN. 13-CYCLES OF TREATMENT FROM 1,577 WOMEN RECRUITED\n* ENDOMETRIAL SAFETY SUBSTUDY ON TRACK TO REPORT TOP LINE RESULTS IN Q3 2018 Source text for Eikon: (Gdynia Newsroom)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T14:01:00.000+03:00", "crawled": "2018-05-04T17:02:55.001+03:00", "highlightTitle": ""}